Treatment patterns of patients with triple-class exposed refractory/relapsed multiple myeloma in Poland — preliminary results of multicentre observational POMOST study

The POMOST study is an ongoing, multicentre, non-interventional, non-randomised observational study of the current management of patients with multiple myeloma (MM) in Poland. We here report preliminary analysis focusing on patients with triple-class exposed (TCE) MM. Subsequent therapeutic interventions after TCE MM diagnosis were analysed and compared to available results from American and European studies. The analysis showed that in the Polish TCE MM patient population, a large majority of patients (69.5%) received two-drug regimens, while three-drug regimens were used in only 30.5%. The most commonly used drugs were lenalidomide (39.0%), carfilzomib (18.6%), bortezomib (18.6%) and pomalidomide (15.3%). In addition, only 60% of patients who received second- and thirdline therapies after a TCE MM diagnosis were given triple-drug therapy based on new drugs, or were treated with new therapies such as CAR-T and belantamab mafodotin. Data from the POMOST study and other available reports indicates that current therapies used in patients with TCE MM are inadequate, and suggest that the treatment of choice in this group of patients should include drugs that have not been used before, and combinations of two new drug classes and three-drug regimens.

Authors

Institutions

Publication Details

Journal
Acta Haematologica Polonica
Published
2025-02-27
DOI
https://doi.org/10.5603/ahp.103294
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Treatment patterns of patients with triple-class exposed refractory/relapsed multiple myeloma in Poland — preliminary results of multicentre observational POMOST study

Aleksandra Butrym, Maria Czyżewska, Katarzyna Warzybok, Wiesława Kosmala-Niewiadomska et al.
Acta Haematologica Polonica
Multiple Myeloma Research and Treatments
article

Treatment patterns of patients with triple-class exposed refractory/relapsed multiple myeloma in Poland — preliminary results of multicentre observational POMOST study

Aleksandra Butrym, Maria Czyżewska, Katarzyna Warzybok, Wiesława Kosmala-Niewiadomska, Olga Czabak, Dominik Dytfeld, Agnieszka Druzd‐Sitek, Magdalena Olszewska‐Szopa, Ewa Lech‐Marańda, Norbert Grząśko, Anna Waszczuk‐Gajda, Tomasz Wróbel, Agnieszka Piebiak, Mateusz Ziarkiewicz, Tadeusz Kubicki, Szymon Fornagiel, Krzysztof Jamroziak, Artur Jurczyszyn, Patryk Węglarz, Jadwiga Hołojda, Agata Tyczyńska, Aleksandra Gołoś, Oliwia Bachanek-Mitura, Jarosław Piszcz, Paweł Bernatowicz, Kamil Wiśniewski, Bartosz Małecki, Marta Morawska, Tomasz Szczepaniak, Elżbieta Kalicińska, Alina Urbanowicz, Lidia Usnarska‐Zubkiewicz, Krzysztof Giannopoulos, Karolina Dołęga-Talacha, Beata Wałachowska, Adrianna Czyż-Szukalska, Sandra Bartyś, Justyna Miedzińska-Król
article en

Abstract

The POMOST study is an ongoing, multicentre, non-interventional, non-randomised observational study of the current management of patients with multiple myeloma (MM) in Poland. We here report preliminary analysis focusing on patients with triple-class exposed (TCE) MM. Subsequent therapeutic interventions after TCE MM diagnosis were analysed and compared to available results from American and European studies. The analysis showed that in the Polish TCE MM patient population, a large majority of patients (69.5%) received two-drug regimens, while three-drug regimens were used in only 30.5%. The most commonly used drugs were lenalidomide (39.0%), carfilzomib (18.6%), bortezomib (18.6%) and pomalidomide (15.3%). In addition, only 60% of patients who received second- and thirdline therapies after a TCE MM diagnosis were given triple-drug therapy based on new drugs, or were treated with new therapies such as CAR-T and belantamab mafodotin. Data from the POMOST study and other available reports indicates that current therapies used in patients with TCE MM are inadequate, and suggest that the treatment of choice in this group of patients should include drugs that have not been used before, and combinations of two new drug classes and three-drug regimens.

Acta Haematologica PolonicaVol. 56(1)
Poznan University of Medical Sciences (PL), Medical University of Lublin (PL), Jagiellonian University (PL), Medical University of Białystok (PL), Medical University of Silesia (PL), Medical University of Warsaw (PL), Torbay Hospital (GB), Wroclaw Medical University (PL), Instytut Hematologii i Transfuzjologi (PL), University of Bydgoszcz (PL), Lublin Oncology Center (PL), Collegium Medicum in Bydgoszcz (PL), Wojewódzki Szpital Zespolony im. Jędrzeja Śniadeckiego (PL), Children's Specialized Hospital (US), National Cancer Research Institute (GB), Gdańsk Medical University (PL), University of Rzeszów (PL)
Openalex Percentile: Top 94%
Multiple Myeloma Research and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.